← Back to all trials
Recruiting
NCT05568719
Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively
Conditions: Hemophilia A, Hemophilia B
Sex: Male
Ages: 18 Years – N/A
Healthy volunteers: No
Phase: PHASE3
Enrollment: 173
Sponsor: Pfizer
Location: The Regents of the University of California||UC Davis Health Rancho Cordova California
Summary
A study to learn about the long-term safety and efficacy of giroctocogene fitelparvovec or fidanacogene elaparvovec in patients with hemophilia A or hemophilia B respectively, who have received treatment through prior participation in a Pfizer-sponsored clinical trial. Data collection and participant visits will be based on standard of care.
Eligibility Criteria
Inclusion Criteria:
-Only participants who received investigational giroctocogene fitelparvovec or fidanacogene eleparvovec and were enrolled in a Pfizer-sponsored study (C0371002, C0371003, C0371005, C3731001, C3731003) are eligible.
Exclusion Criteria:
-None
Source: ClinicalTrials.gov (NCT05568719). StuddyBuddy aggregates publicly available trial information.
